📊 KAYS Key Takeaways
Is KAYS a Good Investment? Thesis Analysis
Company exhibits critical financial distress with negative stockholders' equity of -547.4K (technical insolvency), severe liquidity crisis (0.04x current ratio), and negligible revenue of 22.6K insufficient to cover 2.9M liabilities. Operating cash flow is deeply negative at -459.7K, indicating the current business model is unsustainable and presents extreme solvency risk.
Why Buy KAYS? Key Strengths
- Positive gross margin of 47.9% indicates potential profitability model if revenue scales
- Cash position of 250K provides temporary operational runway
- Pharmaceutical sector offers potential for high-margin products if commercialization succeeds
KAYS Investment Risks to Consider
- Negative stockholders' equity of -547.4K indicates technical insolvency and balance sheet insolvency
- Current ratio of 0.04x signals severe liquidity crisis and immediate going concern risk
- Operating losses of 637.1K against revenue of only 22.6K demonstrate fundamentally broken unit economics
- Negative operating cash flow of -459.7K shows company is burning cash unsustainably
- Long-term debt of 400K exceeds total assets of 199.4K, creating debt-to-asset crisis
- Zero insider activity in 90 days may indicate abandonment or lack of confidence
Key Metrics to Watch
- Revenue growth trajectory - must increase dramatically from 22.6K base
- Operating cash flow improvement - currently negative 459.7K, must turn positive
- Reduction of operating losses relative to revenue
- Equity restructuring or recapitalization to address negative equity position
- Cash burn rate sustainability against 250K cash position
KAYS Financial Metrics
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
KAYS Profitability Ratios
KAYS vs Healthcare Sector
How Kaya Holdings, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is KAYS Overvalued or Undervalued?
Based on fundamental analysis, Kaya Holdings, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
KAYS Balance Sheet & Liquidity
KAYS 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Kaya Holdings, Inc.'s revenue has declined by 99% over the 5-year period, indicating business contraction. The most recent EPS of $0.01 reflects profitable operations.
KAYS Growth Metrics (YoY)
KAYS Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $3.0K | -$2.5M | $-0.06 |
| Q2 2025 | $10.1K | $402.4K | $0.00 |
| Q1 2025 | $7.1K | -$1.1M | $-0.01 |
| Q3 2024 | $3.0K | $1.4M | $0.01 |
| Q1 2024 | $28.0K | $67.2K | N/A |
| Q3 2023 | $59.0K | -$679.2K | N/A |
| Q2 2023 | $55.1K | -$679.2K | N/A |
| Q1 2023 | $48.2K | $34.9K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
KAYS Capital Allocation
KAYS SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Kaya Holdings, Inc. (CIK: 0001530746)
📋 Recent SEC Filings
❓ Frequently Asked Questions about KAYS
What is the AI rating for KAYS?
Kaya Holdings, Inc. (KAYS) has an AI rating of STRONG SELL with 98% confidence, based on fundamental analysis of SEC EDGAR filings.
What are KAYS's key strengths?
Claude: Positive gross margin of 47.9% indicates potential profitability model if revenue scales. Cash position of 250K provides temporary operational runway.
What are the risks of investing in KAYS?
Claude: Negative stockholders' equity of -547.4K indicates technical insolvency and balance sheet insolvency. Current ratio of 0.04x signals severe liquidity crisis and immediate going concern risk.
What is KAYS's revenue and growth?
Kaya Holdings, Inc. reported revenue of $22.6K.
Does KAYS pay dividends?
Kaya Holdings, Inc. does not currently pay dividends.
Where can I find KAYS SEC filings?
Official SEC filings for Kaya Holdings, Inc. (CIK: 0001530746) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is KAYS's EPS?
Kaya Holdings, Inc. has a diluted EPS of $-0.16.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is KAYS a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Kaya Holdings, Inc. has a STRONG SELL rating with 98% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is KAYS stock overvalued or undervalued?
Valuation metrics for KAYS: ROE of N/A (sector avg: 15%), net margin of -56,290.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy KAYS stock in 2026?
Our dual AI analysis gives Kaya Holdings, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is KAYS's free cash flow?
Kaya Holdings, Inc.'s operating cash flow is $-459.7K, with capital expenditures of $27.1K. FCF margin is -2,158.1%.
How does KAYS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -56,290.2% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.04 (avg: 2).